Homocysteine plasma levels in patients treated with antiepileptic drugs depend on folate and vitamin B12 serum levels, but not on genetic variants of homocysteine metabolism

References

1. Sener U, Zorlu Y, Karaguzel O, Ozdamar O, Coker I, Topbas M. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6. Seizure 2006;15:79–85.10.1016/j.seizure.2005.11.002Suche in Google Scholar

2. Gidal BE, Tamura T, Hammer A, Vuong A. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. Epilepsy Res 2005;64:161–6.10.1016/j.eplepsyres.2005.03.005Suche in Google Scholar

3. Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev 2003;25:113–5.10.1016/S0387-7604(02)00163-8Suche in Google Scholar

4. Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol 2011;69:352–9.10.1002/ana.22229Suche in Google Scholar PubMed

5. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015–22.10.1001/jama.288.16.2015Suche in Google Scholar PubMed

6. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. Br Med J 2009;338:a3083.10.1136/bmj.a3083Suche in Google Scholar PubMed PubMed Central

7. Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, et al. Homocysteine, vitamin B12, and folic acid levels in Alzheimer’s disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 2011;27:909–22.10.3233/JAD-2011-110752Suche in Google Scholar PubMed

8. Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 2010;75:1408–14.10.1212/WNL.0b013e3181f88162Suche in Google Scholar PubMed

9. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, et al. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother 2009;9:1393–412.10.1586/ern.09.75Suche in Google Scholar PubMed

10. Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45:1613–22.10.1111/j.0013-9580.2004.17504.xSuche in Google Scholar PubMed

11. Gaitatzis A, Johnson AL, Chadwick DW, Shorvon SD, Sander JW. Life expectancy in people with newly diagnosed epilepsy. Brain 2004;127:2427–32.10.1093/brain/awh267Suche in Google Scholar

12. Aurlien D, Larsen JP, Gjerstad L, Tauboll E. Comorbid and underlying diseases–major determinants of excess mortality in epilepsy. Seizure 2012;21:573–7.10.1016/j.seizure.2012.05.015Suche in Google Scholar

13. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997;38:1062–8.10.1111/j.1528-1157.1997.tb01194.xSuche in Google Scholar

14. Baldelli E, Leo G, Andreoli N, Fuxe K, Biagini G, Agnati LF. Homocysteine potentiates seizures and cell loss induced by pilocarpine treatment. Neuromolecular Med 2010;12:248–59.10.1007/s12017-009-8110-1Suche in Google Scholar

15. Bleich S, Bayerlein K, Hillemacher T, Degner D, Kornhuber J, Frieling H. An assessment of the potential value of elevated homocysteine in predicting alcohol-withdrawal seizures. Epilepsia 2006;47:934–8.10.1111/j.1528-1167.2006.00560.xSuche in Google Scholar

16. Stover PJ. Polymorphisms in 1-carbon metabolism, epigenetics and folate-related pathologies. J Nutrigenet Nutrigenomics 2011;4:293–305.10.1159/000334586Suche in Google Scholar

17. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, et al., editors. The metabolic and molecular bases of inherited disease. New York: Mc Graw-Hill, 2001:2007–56.Suche in Google Scholar

18. Ono H, Sakamoto A, Mizoguchi N, Sakura N. The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev 2002;24:223–6.10.1016/S0387-7604(02)00004-9Suche in Google Scholar

19. Belcastro V, Gaetano G, Italiano D, Oteri G, Caccamo D, Pisani LR, et al. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia 2007;48:1990–4.10.1111/j.1528-1167.2007.01164.xSuche in Google Scholar

20. Caccamo D, Condello S, Gorgone G, Crisafulli G, Belcastro V, Gennaro S, et al. Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromolecular Med 2004;6:117–26.10.1385/NMM:6:2-3:117Suche in Google Scholar

21. Yoo JH, Hong SB. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 1999;48:1047–51.10.1016/S0026-0495(99)90204-4Suche in Google Scholar

22. Sniezawska A, Dorszewska J, Rozycka A, Przedpelska-Ober E, Lianeri M, Jagodzinski PP, et al. MTHFR, MTR, and MTHFD1 gene polymorphisms compared to homocysteine and asymmetric dimethylarginine concentrations and their metabolites in epileptic patients treated with antiepileptic drugs. Seizure 2011;20:533–40.10.1016/j.seizure.2011.04.001Suche in Google Scholar PubMed

23. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–3.10.1038/ng0595-111Suche in Google Scholar PubMed

24. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044–51.10.1086/301825Suche in Google Scholar PubMed PubMed Central

25. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867–74.10.1093/hmg/5.12.1867Suche in Google Scholar PubMed

26. Afman LA, Lievers KJ, van der Put NM, Trijbels FJ, Blom HJ. Single nucleotide polymorphisms in the transcobalamin gene: relationship with transcobalamin concentrations and risk for neural tube defects. Eur J Hum Genet 2002;10:433–8.10.1038/sj.ejhg.5200830Suche in Google Scholar PubMed

27. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A 2004;124:339–45.10.1002/ajmg.a.20505Suche in Google Scholar PubMed

28. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996;59:1262–7.Suche in Google Scholar

29. Wilson A, Leclerc D, Rosenblatt DS, Gravel RA. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum Mol Genet 1999;8:2009–16.10.1093/hmg/8.11.2009Suche in Google Scholar PubMed

30. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.10.1161/01.CIR.93.1.7Suche in Google Scholar